Every 10-Q that Microbot Med Inc (MBOT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MBOT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBOT filings page.
Microbot Medical Inc. reported initial commercial revenue from the LIBERTY® Endovascular Robotic System while remaining in a development-stage loss position. For the quarter ended June 30, 2026, revenue was $241,000, all from LIBERTY system sales, and $346,000 for the first half of 2026. Cost of revenues of $884,000 in the quarter and $987,000 year-to-date resulted in negative gross margin as early production and customer concessions weighed on costs.
Research and development expenses were $1.9 million in the quarter and $3.2 million for six months, while sales, general and administrative expenses rose to $3.7 million for the quarter and $6.7 million year-to-date as the company built out commercialization capabilities. Net loss widened to $5.6 million for the quarter and $9.3 million for six months, reflecting higher operating spending and the absence of prior-year one-time other income. Operating cash outflow was $10.0 million in the first half.
Liquidity remains strong, with $67.4 million in cash equivalents and marketable securities as of June 30, 2026 and shareholders’ equity of $68.9 million. Management concludes these resources are sufficient to fund operations for more than 12 months, but the company expects continued losses as it scales LIBERTY manufacturing and sales. Operations and key suppliers are concentrated in Israel, and the company highlights regional conflict as an ongoing risk it is monitoring.
Microbot Medical Inc. reported its first commercial revenue in the three months ended March 31, 2026 as it began selling the LIBERTY® Endovascular Robotic System. Revenue was $105,000, with cost of revenues of $103,000, resulting in a small gross profit while the business remains in its early launch phase.
The company recorded a net loss of $3.7 million, wider than the $2.6 million loss a year earlier, driven mainly by higher sales, general and administrative expenses as commercialization ramps, partly offset by increased financing income. Cash and cash equivalents were $3.7 million and marketable securities were $68.8 million, supporting total assets of $78.1 million and shareholders’ equity of $74.1 million.
Management notes that available cash and marketable securities are sufficient to fund operations for more than twelve months, even as the company expects continued operating losses while it scales manufacturing, sales, and ongoing development of LIBERTY® and related technologies.
Microbot Medical (MBOT) reported Q3 2025 results, highlighting a larger cash position to support commercialization preparation and ongoing R&D. Cash and cash equivalents were $6.7 million with marketable securities of $73.5 million, bringing total current assets to $80.8 million as of September 30, 2025. The company recorded a net loss of $3.6 million (basic and diluted loss per share of $0.07) for the quarter.
Shareholders’ equity rose to $78.2 million, aided by equity financings and warrant exercises during the year. Shares outstanding were 65,833,556 as of September 30, 2025; the company later reported 67,158,044 shares as of November 12, 2025. Management noted funds are sufficient to operate for more than twelve months from the financial statement issuance date.
Operationally, the FDA granted 510(k) clearance for the LIBERTY Endovascular Robotic Surgical System, and the company increased authorized common shares to 120,000,000 in June 2025 to support capital needs. Marketable securities expanded as proceeds were invested in money market mutual funds.
Microbot Medical, Inc. is a pre-commercial, clinical-stage medical device company developing the LIBERTY® Endovascular Robotic Surgical System. As of June 30, 2025, the company held approximately $4.1 million in cash and $28.6 million in money market mutual funds (marketable securities), totaling about $32.7 million of cash and marketable securities and $33.1 million in total assets. Shareholders' equity rose to $30.4 million from $3.5 million at year-end 2024, primarily driven by equity financings completed in early 2025.
Microbot reported a net loss of $3.5 million for the quarter and $6.1 million for the six months ended June 30, 2025 (basic and diluted loss per share of $0.10 and $0.18, respectively). Operating cash used was $5.4 million for the six months, while financing activities provided $32.6 million of cash. The company remains pre-revenue, has an accumulated deficit of $97.0 million, notes continuing risks from Israeli regional instability, and states management believes available funds plus recent capital raises are sufficient to fund operations for more than twelve months from issuance of these statements.